Robert I. Blum, President and CEO of Cytokinetics Inc., filed a Form 4 on November 2, 2026, reporting the exercise of 7,500 stock options and the same-day sale of 7,500 shares of common stock pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Blum exercised 7,500 non-qualified stock options at an exercise price of $10.60 per share on November 2, 2026, acquiring 7,500 shares (transaction code M).
  • Same-day sale: Blum disposed of 7,500 shares at $62.81 per share on November 2, 2026 (transaction code S).
  • Remaining direct ownership: Following the transactions, Blum directly beneficially owned 278,544 shares of common stock.
  • Options remaining: After the exercise, Blum held 134,245 non-qualified stock options with an exercise price of $10.60 and an expiration date of February 28, 2027.
  • Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
  • Indirect holdings: Blum also holds indirect interests of 2,083 shares each through two irrevocable trusts, though beneficial ownership in those shares is disclaimed.

Robert Blum's Option Exercise and Stock Sale at Cytokinetics

According to the filing, Robert I. Blum, who serves as both a Director and President and CEO of Cytokinetics Inc. (NASDAQ:CYTK), executed two transactions on November 2, 2026. He first exercised 7,500 non-qualified stock options at a conversion price of $10.60 per share, bringing his directly held shares to 286,044. He then sold all 7,500 of those newly acquired shares at $62.81 per share, reducing his direct holdings to 278,544 shares.

The filing notes that the transactions were carried out under a Rule 10b5-1(c) written plan. Following the option exercise, the filing discloses that Blum retains 134,245 non-qualified stock options with the same $10.60 exercise price, originally exercisable from March 28, 2017, and expiring February 28, 2027, with a reported derivative security price of $0.

In addition to his direct holdings, the filing reports that Blum holds 2,083 shares indirectly through The Bridget Blum 2003 Irrevocable Trust and another 2,083 shares through The Brittany Blum 2003 Irrevocable Trust, of which he is a co-trustee. The filing states that Blum "disclaims any beneficial ownership interest" in both sets of trust-held shares. A third trust is listed with 0 shares. The form was signed by John O. Faurescu as attorney-in-fact for Mr. Blum on November 2, 2026.

What Was Disclosed

Blum's Form 4 disclosed the exercise of 7,500 stock options at $10.60 and the sale of 7,500 shares at $62.81 on November 2, 2026, conducted under a Rule 10b5-1 plan, leaving him with 278,544 directly owned shares and 134,245 remaining options.